Apixaban for Extended Treatment of Provoked VTE: New NEJM Study Challenges Treatment Paradigm
Emma P. with Clinical Research Professionals shared a post on LinkedIn:
“Apixaban for Extended Treatment of Provoked Venous Thromboembolism
A recent publication in The New England Journal of Medicine explores the benefits of continuing anticoagulation therapy with apixaban in patients who experienced venous thromboembolism (VTE) due to transient provoking factors like surgery, trauma, or immobility. Traditionally, these patients receive short-term anticoagulation, but this study challenges that paradigm.
Title: Apixaban for Extended Treatment of Provoked Venous Thromboembolism
Authors: Gregory Piazza, Behnood Bikdeli, Arvind K. Pandey, Darsiya Krishnathasan, Candrika D. Khairani, Antoine Bejjani, Ruth H. Morrison, Heather Hogan, Sina Rashedi, Mariana Pfeferman, Junyang Lou, John Fanikos, Nicole Porio, Lisa Rosenbaum, Piotr Sobieszczyk, Zhou Lan, Marie Gerhard-Herman, Umberto Campia, Samuel Z. Goldhaber
* Study Design:
Researchers conducted a randomized, double-blind trial comparing extended apixaban therapy to placebo in patients with provoked VTE who had completed initial anticoagulation. The goal: assess whether continued treatment could prevent recurrence without increasing bleeding risk.
* Key Findings:
• Apixaban reduced recurrent VTE by 82% compared to placebo.
• Major bleeding rates were low and comparable between groups.
• The benefit was consistent across subgroups, including those with persistent risk factors like obesity or cancer history.
* Clinical Implications:
This study suggests that extended apixaban therapy may be appropriate for select patients with provoked VTE, especially when enduring risk factors exist. It calls for a more individualized approach to anticoagulation duration—balancing recurrence risk with bleeding concerns.
* Why It Matters:
VTE remains a leading cause of preventable hospital death. This research could reshape guidelines and improve long-term outcomes for thousands of patients annually.
For clinicians, researchers, and policy-makers: this is a pivotal moment to re-evaluate how we define “provoked” VTE and tailor treatment accordingly.
Clinical and Research Focus
Broader Impact and Engagement.”
Stay updated with Hemostasis Today.
-
Apr 20, 2026, 18:59Chokri Ben Lamine: Contributing to a Landmark Chapter on Amegakaryocytic Thrombocytopenia in Bone Marrow Failure
-
Apr 20, 2026, 18:39David McIntosh: A Watershed Moment for Global Plasma Community and Call for Unified Action
-
Apr 20, 2026, 18:15Nandini Pethe: Grateful for a Fantastic 2026 HFA Symposium Filled with Impactful Educational Sessions and Meaningful Connections
-
Apr 20, 2026, 17:13Armghan Ans: The Stroke Decision Nobody Owns
-
Apr 20, 2026, 17:12Assefa Desalew: RhD-Negative Status and Adverse Perinatal Outcomes in Eastern Ethiopia
-
Apr 20, 2026, 16:55Francesco Lo Monaco: Blood Type and Heart Risk – Small Differences, Bigger Role of Lifestyle
-
Apr 20, 2026, 16:44Supporting the Next Generation in Thrombosis and Hemostasis at ISTH 2026
-
Apr 20, 2026, 16:38Bjorn Logi Thorarinsson: Strengthening Stroke Units Through Certification, Registries, and Evidence-Based Practice
-
Apr 20, 2026, 16:37Domenico Girelli: Anemia Is Linked to Higher Dementia Risk and Elevated Alzheimer’s Disease Biomarkers